ascorbic acid + biotin + cocarboxylase tetrahydrate + 9 other active ingredients: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ascorbic acid + biotin + cocarboxylase tetrahydrate + 9 other active ingredients: clinical details
Prescribing considerations
- Include vitamins from nutrition, supplements and medicines when assessing total exposure.
- Specific deficiencies may require targeted replacement.
- Assess vitamin B12 status when deficiency is possible or prolonged supplementation is anticipated.
- Assess vitamin K separately.
- Confirm compatibility before addition to parenteral nutrition or Y-site administration.
Contraindications and cautions
- Hypersensitivity to an active ingredient or excipient, particularly thiamine.
- Soy or peanut protein or product allergy.
- Hypervitaminosis involving any included vitamin.
- Use additional caution in hepatic or renal impairment because susceptibility to toxicity may be increased.
Monitoring
- Clinical response and relevant vitamin concentrations during prolonged use or when this is the sole vitamin source.
- Liver function and signs of hepatobiliary disease.
- Vitamin A exposure, especially with hepatic disease, severe renal impairment or multiple vitamin sources.
- Vitamin B1 in dialysis and vitamin B6 in renal impairment where clinically indicated.
- Potential biotin or ascorbic-acid interference with laboratory results.
- Infusion-site and systemic hypersensitivity reactions.
Clinical pharmacology
A parenteral combination of water-soluble and fat-soluble vitamins, excluding vitamin K. Components act as enzyme cofactors or support antioxidant defence, cell differentiation, haematopoiesis, connective-tissue metabolism and calcium homeostasis.
Formulation and product differences
- Sterile orange-yellow lyophilised powder requiring reconstitution before intravenous administration.
- Contains 12 vitamins but no vitamin K.
- Contains soy-derived phosphatides and sodium.
- Light, oxygen, bisulfites, alkaline conditions or high calcium concentrations may reduce vitamin stability; compatibility must be established.
ascorbic acid + biotin + cocarboxylase tetrahydrate + 9 other active ingredients interactions
Interactions may arise from individual vitamins. Give the nutrition and medicines teams a complete list of medicines and supplements.
Levodopa
Pyridoxine may reduce levodopa's effect; significance depends on the accompanying Parkinson's treatment.
Phenytoin, fosphenytoin, phenobarbital or primidone
Folic acid may lower anticonvulsant concentrations and increase seizure risk; some anticonvulsants can also increase vitamin requirements.
Warfarin and other vitamin K antagonists
Vitamin E may enhance anticoagulant effects, requiring attention to bleeding risk and monitoring.
Sources
These sources were used to prepare and review this medicine page.
iatroX CPD
Keep a note for CPD
Save a private reflection with this source attached. Your first is free.
Record learning (opens in a new tab)Prepared and reviewed by the iatroX editorial team.